Immunotherapy Plus Chemo Improves Quality of Life in NSCLC Immunotherapy Plus Chemo Improves Quality of Life in NSCLC

In addition to improving overall survival, the PD-1 inhibitor cemiplimab shows improvements in patient-reported quality-of-life measures.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news